The recent arrival of new chief executive officer Pete Yonkman at medical device manufacturer Cook Group Inc. provides a renewed platform for debate with respect to IVC filter lawsuits and where litigation fits in with the recently installed CEO’s list of priorities. The inferior vena cava filter is a medical device that is embedded in the area by which the device is identified, the inferior vena cava, which returns blood from the lower body to the heart.
various IVC lawsuits have taken a handful of manufacturers to task for making and marketing inferior vena cava filters that are – well – inferior. The devices have been known to break apart, move away from the original implantation zone or penetrate the blood vessel wall.You can get more knowledge on IVC filters through http://www.bardfilterlawsuitcenter.com/bard-ivc-filter-lawsuits.asp.
Those manufacturers include C.R. Bard Inc. (Bard), which manufactures the Bard IVC filter. But the Cook filters have proven quite uncertain in their own right for patients. One study referenced by the Indianapolis Business Journal put the failure rate for the Cook IVC filters at 100 percent when implanted for 2.5 months or longer. The failures have for some patients appeared in organ damage and required various medical procedures to remove them.
So far, there are about 100 IVC filter lawsuits pending against Cook alone. Other lawsuits have targeted the Bard G2 IVC filter. But for Yonkman, the Cook lawsuits remain a headache he would like to settle. Beginning in 2012, the lawsuits have since been consolidated in federal court at Indianapolis.